What is EpiBiome?
Founded in 2013 and headquartered in the San Francisco Bay Area, EpiBiome operates at the intersection of genomics and automated drug discovery. The company utilizes a sophisticated technological stack—integrating next-generation sequencing, directed evolution, and machine learning—to engineer phage cocktails designed to address complex bacterial threats. As a former participant in the Illumina Accelerator and the Johnson & Johnson Innovation JLABS ecosystem, EpiBiome has established a robust foundation for its research, effectively bridging the gap between academic innovation and commercial-scale biotechnology development. Its market position is defined by its unique ability to rapidly iterate on phage-based solutions, providing a scalable alternative to traditional antibiotic treatments.
How much funding has EpiBiome raised?
EpiBiome has raised a total of $12.6M across 3 funding rounds:
Private Equity
$5.6M
Series A
$6M
Debt
$1M
Private Equity (2015): $5.6M, investors not publicly disclosed
Series A (2016): $6M led by SV Tech Ventures and ChinaRock Capital Management
Debt (2016): $1M supported by Silicon Valley Bank
Key Investors in EpiBiome
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage & investment services, funds management, and business valuation services.
SV Tech Ventures
A venture capital firm focused on identifying and supporting high-growth technology and life sciences companies through strategic capital and operational guidance.
ChinaRock Capital Management
CRCM L.P. is a registered investment adviser based in San Francisco, providing tailored financial strategies and professional investment management for individuals and institutions.
What's next for EpiBiome?
With the recent capital injection, EpiBiome is poised to transition from its foundational research phase into more intensive clinical validation and commercial scaling. The strategic focus will likely center on expanding its library of phage candidates and optimizing its automated discovery pipeline to meet the rigorous demands of regulatory approval processes. As the firm continues to refine its proprietary platform, it remains well-positioned to address the growing global challenge of antibiotic resistance. Future growth will depend on the successful translation of its laboratory-proven phage cocktails into effective therapeutic interventions, potentially attracting further interest from large-scale pharmaceutical partners seeking to bolster their infectious disease portfolios.
See full EpiBiome company page
